Targeting IDO represents a therapeutic option in cancer immunotherapy, and several phase I and II studies have explored the role of 1-MT, alone or in combination with docetaxel, sipuleucel-T, or ipilimumab, in breast, prostate, pancreas, and other cancers [134]. This evidence concerns the gene IDO1 and cancer.